600th Heart Attack Patient Recruited into Phase III CicloMulsion(R) CIRCUS Trial PharmaLive (press release) (subscription) NeuroVive, a leading mitochondrial medicine company, announces that the 600th patient has been recruited to a pivotal Phase III European, multi-center trial (CIRCUS trial) assessing CicloMulsion® (a special formulation of cyclosporine for acute cardiac ... |
